Showing results (21-30 of 209) with videos related to
Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cellsSven Gottschalk, Nora Anderson, Carsten Hainz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Accelerated approval and breakthrough therapy designation: oncology drug development on speed?James C Yao, Funda Meric-Bernstam, J Jack Lee, et al.Journal of Immunotherapy and Precision Oncology|June 27, 2022
Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging ParadigmsMihailo Miljanic, Anna Capasso, Todd A Triplett, et al.Pharmacology & Therapeutics|December 24, 2013
Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitorsTodd M Pitts, S Lindsey Davis, S Gail Eckhardt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2Jennifer L Spratlin, Roger B Cohen, Matthew Eadens, et al.Journal of the National Cancer Institute|September 21, 2013
From bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentChristopher H Lieu, Aik-Choon Tan, Stephen Leong, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2009
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selectionAntonio Jimeno, Wells A Messersmith, Fred R Hirsch, et al.Cancer Journal (Sudbury, Mass.)|April 25, 2009
KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancerAntonio Jimeno, Wells A Messersmith, Fred R Hirsch, et al.Investigational New Drugs|August 31, 2002
A phase II study of Irofulven (MGI 114) in patients with stage IV melanomaA Scott Pierson, Peter Gibbs, Jon Richards, et al.Molecular Cancer Therapeutics|January 29, 2009
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell modelsTodd M Pitts, Mark Morrow, Sara A Kaufman, et al.Pageof 21